ArticleNature2023
p53 governs an AT1 differentiation programme in lung cancer suppression.
Open access · greenAbstract read
In one paragraph
Article in Nature, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
67citing papers in PubMed, 1 pooled it
21.5field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
67 citing papers in PubMed, 1 synthesis or guideline pooled it, 83 citations in OpenAlex.
- Innovative technologies and their clinical prospects for early lung cancer screening.Clinical and experimental medicine · 2025Pooled it
- Article
- Engineered bacteria as exogenous organelle mimics restore PTEN and p53 tumor suppressor functions for cancer therapy.Nature communications · 2026Article
- Cellular hallmarks and aging clock of the human lung parenchyma.Nature communications · 2026Article
- Transitional cell states at the crossroads of development, disease, and repair-regeneration.Physiological reviews · 2026Review
- LFPM inhibition of RING1-mediated p53Cell death and differentiation · 2026Article
- Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma.Molecular oncology · 2026Article
- Article
- Screening air pollutants-related genes to construct a prognostic risk model for lung adenocarcinoma and analyzing its immune microenvironment.Journal of thoracic disease · 2026Article
- EBF3 suppresses lung adenocarcinoma progression and immune evasion via transcriptional repression of CCL24.Cellular oncology (Dordrecht, Netherlands) · 2026Article
- Tolerance and Resistance to Targeted Therapy in NSCLC: Emerging Concepts and Strategies.JTO clinical and research reports · 2026Review
- TP53/TAU axis regulates microtubule bundling to control alveolar stem cell-mediated regeneration.The Journal of clinical investigation · 2026Article
- Article
- Epithelial plasticity shapes intratumoral heterogeneity and cell lineages in early-stage lung cancer.Science advances · 2026Article
- Identification and validation of prognostic genes associated with integrative stress response in lung adenocarcinoma and construction of the risk models.Scientific reports · 2026Article
- Single-nucleus multi-omics delineates distinct epigenetic programs associated with tumor progression in lung adenocarcinoma.Clinical epigenetics · 2026Article
- p53 Drives Lung Cancer Regression through a TSC2/TFEB-dependent Senescence Program.Cancer discovery · 2026Article
- Theragenerative Nanomaterials: Integrating Therapy, Regeneration, and Diagnosis-Navigating the Shared Pathways Between Tissue Repair and Malignancy.International journal of nanomedicine · 2026Review
- Risk factors for fast-growing lung cancers detected on chest CT: a retrospective cohort study.Frontiers in oncology · 2026Article
- Evolution of Cancer Metastases via Lineage Trans-Differentiation.Research (Washington, D.C.) · 2026Article
7 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 3 institutions in 2 countries.
Alyssa M KaiserDivision of Radiation and Cancer Biology, Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA, USA.
Alberto Gatto *Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0002-8378-0131
Kathryn J Hanson *Division of Radiation and Cancer Biology, Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA, USA.
Richard L ZhaoDivision of Radiation and Cancer Biology, Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0001-9626-143X
Nitin RajDivision of Radiation and Cancer Biology, Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0001-7678-3855
Michael G OzawaDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
José A SeoaneCancer Computational Biology Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.ORCID 0000-0002-3856-9177
Kathryn T Bieging-RolettDivision of Radiation and Cancer Biology, Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA, USA.
Mengxiong WangDivision of Radiation and Cancer Biology, Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA, USA.
Irene LiDepartment of Biomedical Data Science, Stanford University School of Medicine, Stanford, CA, USA.
Winston L TropeDivision of Thoracic Surgery, Department of Cardiothoracic Surgery, Stanford University School of Medicine, Stanford, CA, USA.
Douglas Z LiouDivision of Thoracic Surgery, Department of Cardiothoracic Surgery, Stanford University School of Medicine, Stanford, CA, USA.
Joseph B ShragerDivision of Thoracic Surgery, Department of Cardiothoracic Surgery, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0003-0859-0589
Sylvia K PlevritisDepartment of Biomedical Data Science, Stanford University School of Medicine, Stanford, CA, USA.
Aaron M NewmanDepartment of Biomedical Data Science, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0002-1857-8172
Capucine Van RechemDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0002-5408-6124
Laura D AttardiDivision of Radiation and Cancer Biology, Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA, USA. attardi@stanford.edu.ORCID 0000-0003-1782-9045
Stanford University · USStanford Medicine · USVall d'Hebron Institute of Oncology · ES
Funding
Leveraging innovative technologies in basic and clinical cancer researchT32CA009302 · NCI · STANFORD UNIVERSITY · PI LAURA D ATTARDI, Aaron M Newman · 1985 to 2026
$19.1MIntegrative approaches to elucidate p53 transcriptional networks during carcinogenesisR35CA197591 · NCI · STANFORD UNIVERSITY · PI LAURA D ATTARDI · 2015 to 2026
$11.6MNCI NIH HHS R35 CA197591NCI NIH HHS T32 CA009302
Abstract
Lung cancer is the leading cause of cancer deaths worldwide
Indexed as
Alveolar Epithelial CellsCell DifferentiationLungLung NeoplasmsTumor Suppressor Protein p53AllelesAnimalsCell LineageCell Self RenewalChromatin Assembly and DisassemblyDisease ProgressionDNAGene Expression ProfilingLung InjuryMiceMice, KnockoutDNAHras protein, mouseProto-Oncogene Proteins p21(ras)Trp53 protein, mouseTumor Suppressor Protein p53
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.